September 15, 2026 · Phase 2 readout
DSGN Phase 2 readout: a negative outcome, -9.5%
On September 15, 2026, DT-168 — Design Therapeutics, Inc. (Fuchs Endothelial Corneal Dystrophy) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -9.5% in the window around the event.
The move
$13.52
1d before
$12.23
Event day
$12.23
1d after
$12.23
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.3% expected); the stock actually moved -9.5%. Model confidence at the time: 100%.
See the full scored track recordPre-catalyst setup
-1.3%
30-day run-up
4187%
30-day volatility
2.1×
volume spike